Blockchain Registration Transaction Record
Quantum BioPharma’s Lucid-MS Aims to Halt Multiple Sclerosis
Quantum BioPharma's Lucid-MS enters phase 2 trials to halt multiple sclerosis progression. Learn how this novel therapy targets myelin repair, offering hope for millions living with MS.
This news matters because it addresses a critical gap in multiple sclerosis (MS) treatment: no current therapy can stop the disease's progression. For the 2.9 million people living with MS, this means a future of worsening disability. Quantum BioPharma's Lucid-MS, if successful, could fundamentally change the outlook for patients by repairing myelin and halting the disease, offering hope for a cure where none exists today. This breakthrough could transform the standard of care and improve millions of lives.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x2698055ac7621b418b12d3e123c48c41a537bbad71e24ab0fbc9785ed697a53b |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | rushz6iV-6b21ee1564aa7e9bf78d8836caef98f6 |